Definitive Therapy for Oligometastatic Solid Malignancies
Status unconfirmed · Phase 2
Conditions studied: Stage IV or Recurrent Carcinoma or Sarcoma
In brief
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival. In the setting of increasingly effective systemic therapy and limited metastatic disease, aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival.
Key facts
- Study ID
- NCT01898962
- Run by
- Rocky Mountain Cancer Centers
- People needed
- 110
- Starts
- 2005-12-01
- Expected to finish
- 2018-12-01
- Last updated by the study team
- 2013-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 4 or less distinct sites of active disease. Locoregional disease counts as one site
- All sites of disease can safely be encompassed by radiation fields to doses ≥ 45 Gy (biologic equivalent dose) and/or removed completely with surgery and/or completely ablated with other appropriate site-specific techniques.
- sufficient blood cell counts and adequate liver function
You may not qualify if…
- Hematologic malignancies
- Distinct sites of disease > 4
- Karnofsky Performance Status < 70
- Unexplained weight loss > 10 %
- HIV, chronic viral hepatitis, or any chronically active infection
- Life expectancy < 6 months for any reason
Where it is running
- Rocky Mountain Cancer Centers - Aurora — Aurora, Colorado, United States (enrolling)
- Rocky Mountain Cancer Centers - Boulder — Boulder, Colorado, United States (enrolling)
- Rocky Mountain Cancer Centers - Littleton — Littleton, Colorado, United States (enrolling)
- Rocky Mountain Cancer Centers - Thornton — Thornton, Colorado, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.